Triaminic Vapor Patch Adverse Events Prompt Recall By Novartis
This article was originally published in The Tan Sheet
Executive Summary
Eight complaints of adverse health effects resulting from accidental ingestion of the Triaminic Vapor Patch have prompted a nationwide recall of products in the line by Novartis Consumer Healthcare
You may also be interested in...
Environmental Group Opposes FDA Adding Triclosan To OTC Monographs
Environmental regulations could impede a group's attempt to block all non-medical uses of triclosan - including in OTC products
Environmental Group Opposes FDA Adding Triclosan To OTC Monographs
Environmental regulations could impede a group's attempt to block all non-medical uses of triclosan - including in OTC products
WellPatch Vapor Pads recalled
FDA and Metholatum have issued a voluntary recall for WellPatch Cough & Cold Soothing Vapor Pads due to the possibility of pediatric ingestion. The topical cough suppressant label indicates the product is suitable for children 2 years and older. The placement of the products on the chest gives young children easy access to remove the patches from their chests and possibly ingest them. Adverse events associated with menthol ingestion range from minor symptoms to seizures, an FDA MedWatch release notes. No serious adverse events linked to the WellPatch product have been reported to date. Triaminic Vapor Patches were similarly recalled in June 2006 due to reported adverse events related to pediatric ingestion (1"The Tan Sheet" June 26, 2006, p. 8)...